Human Experimental Neuropsychopharmacology, IIB Sant Pau, Barcelona, Spain.
PLoS One. 2012;7(8):e42421. doi: 10.1371/journal.pone.0042421. Epub 2012 Aug 8.
Ayahuasca is an Amazonian psychoactive plant beverage containing the serotonergic 5-HT(2A) agonist N,N-dimethyltryptamine (DMT) and monoamine oxidase-inhibiting alkaloids (harmine, harmaline and tetrahydroharmine) that render it orally active. Ayahuasca ingestion is a central feature in several Brazilian syncretic churches that have expanded their activities to urban Brazil, Europe and North America. Members of these groups typically ingest ayahuasca at least twice per month. Prior research has shown that acute ayahuasca increases blood flow in prefrontal and temporal brain regions and that it elicits intense modifications in thought processes, perception and emotion. However, regular ayahuasca use does not seem to induce the pattern of addiction-related problems that characterize drugs of abuse. To study the impact of repeated ayahuasca use on general psychological well-being, mental health and cognition, here we assessed personality, psychopathology, life attitudes and neuropsychological performance in regular ayahuasca users (n = 127) and controls (n = 115) at baseline and 1 year later. Controls were actively participating in non-ayahuasca religions. Users showed higher Reward Dependence and Self-Transcendence and lower Harm Avoidance and Self-Directedness. They scored significantly lower on all psychopathology measures, showed better performance on the Stroop test, the Wisconsin Card Sorting Test and the Letter-Number Sequencing task from the WAIS-III, and better scores on the Frontal Systems Behavior Scale. Analysis of life attitudes showed higher scores on the Spiritual Orientation Inventory, the Purpose in Life Test and the Psychosocial Well-Being test. Despite the lower number of participants available at follow-up, overall differences with controls were maintained one year later. In conclusion, we found no evidence of psychological maladjustment, mental health deterioration or cognitive impairment in the ayahuasca-using group.
安非他命是一种亚马逊精神活性植物饮料,含有血清素能 5-HT(2A) 激动剂 N,N-二甲基色胺 (DMT) 和单胺氧化酶抑制生物碱(哈梅林、哈马灵和四氢哈马灵),使其具有口服活性。安非他命的摄入是几个巴西融合教堂的核心特征,这些教堂已经将其活动扩展到巴西城市、欧洲和北美。这些团体的成员通常每月至少摄入两次安非他命。先前的研究表明,急性安非他命会增加前额叶和颞叶脑区的血流量,并且会引起思维过程、感知和情绪的强烈改变。然而,定期使用安非他命似乎不会引起滥用药物所特有的与成瘾相关的问题模式。为了研究重复使用安非他命对一般心理健康、精神健康和认知的影响,我们在这里评估了定期安非他命使用者(n = 127)和对照组(n = 115)的人格、精神病理学、生活态度和神经认知表现,基线和 1 年后。对照组积极参与非安非他命宗教。使用者表现出更高的奖励依赖和自我超越,更低的回避和自我导向。他们在所有精神病理学测量中得分明显较低,在 Stroop 测试、威斯康星卡片分类测试和 WAIS-III 的字母数字序列任务中表现更好,在额叶系统行为量表上得分更高。生活态度分析显示,精神取向量表、生活目的测试和心理社会健康测试的得分更高。尽管在随访时可用的参与者人数较少,但一年后与对照组的总体差异仍得以维持。总之,我们没有发现使用安非他命的群体存在心理失调、精神健康恶化或认知障碍的证据。